GEN - Genetic Engineering and Biotechnology News

Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Points

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...
The Bakersfield Californian

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial ...

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...
IEEE

Design of Intelligent Analysis Method for E-Commerce Data Based on Improved Bayesian Algorithm

Abstract: It is frequently difficult to handle large-scale, high-dimensional data using traditional e-commerce data analysis methodologies, which makes it challenging to effectively capture user ...
IEEE

New Scheduling Algorithm and Analysis for Partitioned Periodic DAG Tasks on Multiprocessors

Abstract: Real-time systems are increasingly shifting from single processors to multiprocessors, where software must be parallelized to fully exploit the additional computational power. While the ...